Discover the top 10carbonreduction strategies for pharma manufacturers in 2025. Optimize your sustainability efforts now—download our expert guide today!
Pharmaceuticalcompanies are prioritizingcarbonfootprintreduction as part of their public sustainability goals, but decarbonization presents unique challenges for theindustry. This article examines those challenges and offers high-impact strategies to overcome them, helping companies improve efficiency while achieving their sustainability targets.
How can thepharmaceuticalindustryovercome barriers toreducingitscarbonfootprint? Despite ongoing efforts to reduce greenhouse gas (GHG) emissions, atmospheric CO2 levels continue to climb, posing significant concern to the escalating climate crisis.
Greenhouse gas emissions related topharmaceuticalshave risen substantially and are likely to continue to rise without concerted and coordinated action. Pharmacies and researchers should investigate sources of unnecessarypharmaceuticaluse and waste, theindustryshould improve supply chain efficiency, governments should promotepharmaceuticalwaste reduction programmes, and international ...
Discover why Scope 3 emissions account for 92% of thepharmaceuticalindustry'scarbonfootprintand how companies can reduce their environmental impact. Learn key strategies for achieving net-zero sustainability.
How Big Is Pharma'sCarbonFootprint? Highlights From My Green Lab's 2025 Impact Report Despite political and economic headwinds, the biotech and pharma sectors are making promising climate commitments.
Pharma companies have launched efforts to reduce the supply chain's environmentalfootprint. Deloitte survey findings reveal what companies have accomplished and what future iniatitives they're working on.
